There are now more adults (>16 years) than children with congenital heart disease (CHD) in Australasia. Previous data suggest that up to 5% may have pulmonary hypertension (PAH). However, registry data are lacking: the prevalence, characteristics, treatment patterns, and outcomes are not well characterized. We therefore established a binational registry to address some of these questions. A comprehensive database was developed. After appropriate ethics approvals were obtained, subjects from all the major adult CHD units in Australia and New Zealand were identified. Patients were included if they had been seen at least once after January 1, 2000, with an established diagnosis of PAH complicating CHD. Three-hundred sixty patients have been entered into the registry. Sixty percent of the patients were female and 85% Caucasian. Patients had their first diagnosis of CHD at 7.94 AE 15.01 years. Age at first visit to the ACHD center was 31.2 AE 13.99 years. Patients recognized their first symptom at age 24.6 AE 16.45 years, exposing a 6.48 AE 8.91-year interval between symptom recognition and adult-center diagnosis of PAH. Dyspnea was the primary presenting symptom in 85% of patients. Diagnosis was based on right heart study in 58% of patients and on echo only in 32%, with 2% based on clinical findings alone. Sixty-four percent and 65% of patients, respectively, had established RVH and dilation on echocardiogram. Underlying CHD diagnoses in these subjects were ASD (21%), PDA (15%), VSD (34%), AVSD (14%), and the remaining, complex lesions (18%). Thirty-four percent of patients underwent surgical repair, 68% had Eisenmenger syndrome, and 24% had Down syndrome. Functional class (FC) at first ACHD center visit was FC III in 56% of cases and FC II in 34%. Mean 6MWT was 364 m at baseline diagnosis. Survival estimates were 88%, 79%, and 69%, respectively, at 5, 10, and 15 years of follow-up. Baseline walk test had a significant impact on survival. The ANZ PAH-CHD database is one of the largest international registries addressing this question. Substantial delays in adult diagnosis exist. Significant collaboration is warranted to address this delay in presentation, which may impact long-term outcomes.
Macitentan, a novel dual endothelin receptor antagonist, significantly reduced the risk of morbidity and mortality (primary end point) in PAH in the SERAPHIN study (NCT00660179). A significant reduction in hospitalization for PAH and death due to PAH (secondary end point) versus placebo was also achieved with macitentan (3 mg: 33%, P ¼ 0.0146; 10 mg: 50%, P < 0.0001). The effect of macitentan on other hospitalization-related end points is reported. Patients (!12 years) with PAH in WHO functional class (FC) II-IV were randomized to oral macitentan 3 mg (n ¼ 250), macitentan 10 mg (n ¼ 242), or placebo (n ¼ 250) once daily in this doubleblind outcomes trial. Time to PAH-related hospitalization up to end of treatment was evaluated via Kaplan-Meier analysis. Annual rates of PAHrelated hospitalizations and inpatient hospital-days up to end of treatment were analyzed (adjusted for baseline WHO FC and 6-minute walk distance). Overall, 33%, 23%, and 20% of placebo, macitentan 3 mg, and macitentan 10 mg patients, respectively, were hospitalized at least once for PAH. Reductions in risk of PAH-related hospitalization (3 mg: 39%, P ¼ 0.0040; 10 mg: 50%, P ¼ 0.0001), annual rates of hospitalization (3 mg: 43%, P ¼ 0.0068; 10 mg: 55%, P ¼ 0.0002), and inpatient hospital days (3 mg: 33%, P ¼ 0.2707; 10 mg: 52%, P ¼ 0.0416) with macitentan are shown. Macitentan significantly reduced the risk of hospitalization for PAH and the number of PAH-related hospitalizations and inpatient days (10 mg only) per year. These data provide further evidence that macitentan beneficially impacts long-term PAH-related outcomes.
The prevalence and consequences of perioperative diastolic dysfunction with pulmonary hypertension in an elderly population class II vs. I; P < 0.001) but did not have significantly prolonged hospital stays (P ¼ 0.61). Diastolic dysfunction, identified using echocardiographic criteria, was seen in the majority of over-60-year-olds without overt cardiorespiratory disease in this study. It was also frequently associated with pulmonary hypertension. Patients with both LVDD and PHT tend to be symptomatic and have a more limited functional class. Populationbased studies would appear to be the next step to help to more precisely define prevalence, but more importantly to determine the natural history of asymptomatic LVDD in the older person.
Noninvasive stress testing of the pulmonary circulation using dobutamine echocardiography P Choudhary, E Lau, L Simmons, T Corte, D Celermajer Royal Prince Alfred Hospital, Sydney, Australia
Our aim was to investigate the role of dobutamine stress echocardiography for noninvasive detailed physiological assessment of the pulmonary circulation. Stress testing of the pulmonary circulation (via increasing pulmonary blood flow) enables determination of multipoint mean pulmonary artery pressure-cardiac output (mPpa-Q) relationships. Dobutamine-induced mPpa-Q relationships could provide additional pathophysiologic insights allowing early identification of pulmonary vascular disease. Thirty-eight subjects (pulmonary arterial hypertension [PAH]: n ¼ 16, age 56 AE 9 years; and healthy controls: n ¼ 22, age 46 AE 16 years) underwent dobutamine stress echocardiography using an incremental dose protocol (up to 20 μg/ kg/min). Another healthy control group (n ¼ 22, age 44 AE 13 years) underwent exercise echocardiography at progressive workloads. Multipoint mPpa-Q plots were analyzed, and the pulmonary vascular distensibility coefficient α was calculated. Dobutamine stress echocardiography was feasible and informative in 93% of subjects. The average dobutamine-induced mPpa-Q slope was 1.1 AE 0.7 mmHg/L/min in healthy controls and 5.1 AE 2.5 mmHg/L/min in PAH patients (P < 0.001). Dobutamine-induced α was markedly reduced in PAH patients (0.003 AE 0.001/mmHg vs. 0.02 AE 0.01/mmHg in controls, P < 0.001). When exercise and dobutamine stress were compared in healthy controls, exercise-induced mPpa-Q slope was modestly higher (2.2 AE 1.7 mmHg/L/min, P ¼ 0.008 vs. dobutamine).
In PAH patients, NYHA functional class status was associated with dobutamine-induced mPpa-Q slopes (P ¼ 0.013) but not with resting total pulmonary vascular resistance. In conclusion, noninvasive assessment of pulmonary mPpa-Q relationships is feasible with dobutamine stress, with marked differences shown between controls and PAH patients. Dobutamine stress echocardiography may potentially be a valuable noninvasive technique for stress testing of the pulmonary vasculature.
Assessment of ventriculoarterial interaction in pulmonary arterial hypertension using wave intensity analysis The assessment of right ventricular afterload is of fundamental importance in pulmonary arterial hypertension (PAH). We present a time domain approach using wave intensity analysis (WIA) to describe ventriculoarterial interactions of the pulmonary circulation. High-fidelity pressure and Doppler flow velocity measurements were made in the pulmonary arteries (PA) in 6 PAH patients and 7 controls. WIA was applied to determine wave speed and to quantify wave energy for the separate forward-and backward-traveling waves. Three consistent waves were present in both PAH patients and controls: (1) an early-systolic forward compression wave (FCW); (2) a late-systolic forward expansion wave (FEW); and (3) (41 months). Three hundred eighty-three initial applications led to 308 approvals (80%), 6 withdrawals, and 68 declines (18%). Of 265 patients starting treatment since July 2009, 163 (62%, 37.1 per million population) continued to receive PAH medication by December 2012, with most ex-recipients having died or undergone transplantation. Overall survival data were influenced by patients who had initiated therapy prior to the panel being established: in effect, "prevalent" rather than "incident" patients. Seventy approvals were for patients under 10 years of age. Indications were predominately congenital/persistent pulmonary hypertension of the newborn (n ¼ 47) or to improve a Fontan circulation (n ¼ 10); 6 children had idiopathic PAH. Twelve patients with Eisenmenger physiology were approved for vasodilator therapy. Use of combination therapy has not increased appreciably and currently comprises 28% of patients. For adult patients with group 1 PAH, the proportion receiving combination therapy is 24%-30% overall. In conclusion: (1) management via a special panel seemly reduces the inappropriate use of pulmonary vasodilator therapy; (2) we have observed a significant and unforeseen demand for these therapies in neonates and infants; and (3) decision by a panel may be a cost-effective way to provide appropriate access, including combination therapy.
Oxygen desaturation during the 6-minute walk test is related to endexercise breathing efficiency and PETCO 2 in congenital heart disease (CHD)-associated pulmonary hypertension 20°C) to enable complete endarterectomy. Two patients with pulmonary angiosarcoma were excluded. Patients were New York Heart Association (NYHA) classes II (n ¼ 2), III (n ¼ 11), or IV (n ¼ 4) preoperatively. Follow-up was at 3, 6, and 12 months. Pulmonary vascular resistance improved immediately postoperatively, from 889 AE 362 to 332 AE 81 dynes/s/ cm 5 (P ¼ 0.00001). Mean pulmonary arterial pressure fell from 50.6 AE 11.9 to 31.0 AE 4.1 mmHg (P ¼ 0.0000002). Cardiac index improved from 2.1 AE 0.5 to 2.6 AE 0.5 L/min/m 2 (P ¼ 0.005). Six-minute-walk test scores increased from 297 AE 124 m preoperatively to 418 AE 55 m at 6 months post-PEA (P ¼ 0.009) and 428 AE 64 m at 12 months post-PEA (P ¼ 0.004). One mortality (5.6%) resulted from persistent pulmonary hypertension in a patient with preoperative decompensated right heart failure, in whom PEA was performed as a salvage procedure. At last follow-up, patients were NYHA classes I (n ¼ 5), II (n ¼ 10), or III (n ¼ 1), with 2 patients awaiting 3-month follow-up. Mean bypass time was 333 AE 86 minutes, and mean DHCA time was 48 AE 17 minutes. We conclude that in CTEPH patients with surgically accessible disease, PEA leads to immediate reduction in pulmonary pressures followed by significant improvements in exercise capacity and quality of life.
The psychosocial burden of intravenous epoprostenol in patients with pulmonary arterial hypertension P Ve, K O'Brien, N Brar, F Kermeen Prince Charles Hospital, Brisbane, Australia
Despite intravenous (IV) epoprostenol improving survival and exercise capacity, health professionals have limited knowledge about the lifestyle changes and psychosocial burden facing patients diagnosed with pulmonary arterial hypertension (PAH). Our aim was to investigate and understand the physical, social, emotional, and practical burdens of delivering IV epoprostenol to improve the provision of complex medical therapies and quality of life in PAH patients. A quantitative survey using open-ended questions, pictorial representations, and the disease-specific Cambridge Pulmonary Hypertension Outcome Review (Camphor) was distributed to patients from a tertiary PAH center in Queensland. Seventy percent of patients responded (16 female, 4 male; 2 were excluded), with 14% aged 16 -40 years, 65% 40 -60 years, and 21% >60 years on triple PAH therapy for a mean of 26 months. More than half of all participants reported that CADD pumps were excessively heavy and annoying to carry and interfered with work, housework, showering, dressings, caring for children, recreational activities, and being intimate with their partners. Social stigma was highly experienced in all participants, leading to social isolation, frustration, and uncertainty. Participants aged 40 -60 years reported more technical problems with the pump, particularly dealing with alarms, removing air from lines, and priming the cassette. Data compiled from the Camphor questionnaire remain to be presented. Our data suggest that health professionals underappreciate the significant practical and psychosocial burden of patients living with a diagnosis of PAH and requiring advanced therapies. Furthermore, greater resources are required to explore and improve delivery systems of IV epoprostenol.
New method for the diagnosis of pulmonary hypertension M Lysenkov, T Martynuk, V Sergienko, I Chazova Russian Cardiology Research and Production Complex, Moscow, Russia
Pulmonary arterial hypertension (PAH) is a devastating lung vascular disease. Despite advances in the diagnosis of this condition, early detection and ascertainment of the genesis of pulmonary hypertension are still a dif-ficult task. We supposed that the method of a single-photon emission computed tomography-computed tomography (SPECT/CT) imaging facility is a good alternative in the diagnosis of the genesis of pulmonary hypertension, especially in the early period of the disease and in patients with complex differential diagnosis. We examined 10 people with suspected pulmonary hypertension. Previously, patients underwent right heart catheterization and CT angiography. Three patients' diagnoses of pulmonary hypertension were not confirmed; in 4 cases idiopathic pulmonary hypertension was suspected and in 3 cases pulmonary embolism. After that, the 7 patients with pulmonary hypertension underwent SPECT/CT with intravenous injection of the radiopharmaceutical 99 Tc-MAA (macroaggregates of albumin). Because of the capabilities of SPECT/CT to assess perfusion at the level of subsegmental pulmonary arteries, a diagnosis of pulmonary embolism was additionally established in 2 patients from the group with idiopathic pulmonary hypertension. In the other cases, the diagnoses were correct. In our data, we established that the use of SPECT/CT has helped us to establish the correct diagnosis that allows us to assign proper and timely treatment. So we confirmed our hypothesis that the modern method of diagnosis of pulmonary hypertension-SPECT/CT-is no less accurate than the standard methods and is probably preferable in difficult diagnostic cases.
"Can we do it better?" P Ve, K O'Brien, N Brar, F Kermeen Prince Charles Hospital, Brisbane, Australia
Continuous intravenous epoprostenol improves pulmonary arterial hypertension (PAH) patients' exercise capacity, quality of life, and long-term survival but requires intensive education in the safe and compliant administration of prostacyclin and CADD pumps on a continual basis. Our aim was to evaluate PAH patient's satisfaction with educational material delivered during the institution of IV epoprostenol from a tertiary PAH center in Queensland. Ninety-five percent of patients responded, with 31% aged 16-40 years, 46% 40-60 years, and 23% >60 years. Average time of triple PAH therapies was 17.6 months. Carers are responsible for preparation of drug in 25% of patients 16-40 years old, 16% of those 40-60 years old, and 33% of those >60 years old. Only 75% of patients aged 16-40 years were satisfied with the education booklet, and 75% of those aged 16-40 years and 50% of those aged 40-60 years asked that educational material be available on either USB, a video clip on YouTube, or an app on iPhone or iPad. All age groups asked for more information on Hickman line infections. In conclusion, PAH patients are generally satisfied with current educational material, but the younger cohort requested materials to be provided through social media, including the development of apps to phones and tablets. Patient support groups provide significant support, which can complement contemporary medical care. A patient pulmonary hypertension (PHT) support group and a follow-up newsletter were established in 2009 by a dedicated social worker with experience in PHT. Review of the literature suggests that little is known about how often these services are actually used in clinical practice or the factors that influence participation. Our aim was to evaluate patients' perceptions and the belief systems of the patient support group and newsletter. We undertook a quantitative survey of 200 patients who attended tertiary PHT service in Queensland. Seventynine (39.5%) of the 200 questionnaires were returned. Eighteen patients (22%), aged 17-67 years, and their carers who lived in metropolitan Brisbane attended the support group regularly and reported personal gains
Receptor type II (BMPRII) mutation-associated PAH, or from high-output cardiac failure. There are no controlled trials of therapy in HHT-PAH, with therapy described in limited case reports only. We present an unusual case of HHT-PAH, in which a 20-year-old woman presented with reduced effort capacity to 10 m. Investigations found a large left-lung arteriovenous malformation with shunt of 8%. Severe pulmonary hypertension was confirmed by echocardiography and right heart catheteriza-tion. The patient was successfully treated with bosentan and then combination therapy with sildenafil, with marked improvements in 6-minute walk test and functional status. Current evidence and therapeutic options are discussed, including the benefits and risks of arteriovenous malformation closure. We conclude that results of this case study add weight to previous reports supporting the use of bosentan and sildenafil in HHTassociated PAH.
